CORONA — Corona Remedies Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Annual income statement for Corona Remedies, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS
Standards:	IAS	IAS	IAS
Status:	Final	Final	Final
Revenue
Total Revenue	8,841	10,145	11,964
Cost of Revenue
Gross Profit	6,731	7,876	9,599
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	7,761	8,865	9,927
Operating Profit	1,080	1,280	2,037
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,109	1,185	1,985
Provision for Income Taxes
Net Income After Taxes	849	905	1,494
Net Income Before Extraordinary Items
Net Income	849	905	1,494
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	849	905	1,494
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	13.9	14.9	24.5